- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02809326
Trauma Management Therapy for OEF and OIF Combat Veterans (TMT)
Study Overview
Status
Conditions
Detailed Description
Background: Troop deployment for OIF/OEF has been extensive for the past five years Among returning veterans, up to 18.5% are diagnosed with posttraumatic stress disorder (PTSD). In addition to its positive symptoms (intrusive thoughts, reexperiencing, hyperarousal, and avoidance), PTSD is associated with social maladjustment, poor quality of life, medical comorbidity, and general symptom severity. Social and emotional problems include social avoidance, guilt, anger, and unemployment, impulsive or violent behavior, and family discord. A majority (> 90%) of veterans seeking treatment for PTSD also seek disability compensation for debilitating occupational impairment and there are virtually no administrative or research data to indicate veterans are recovering from PTSD. Exposure therapy, which operates on long-established and fundamental principles of behavior therapy, offers hope for acute symptom alleviation, but may not address severe social impairment.
Objectives/Hypothesis: To test the hypothesis that Trauma Management Therapy (TMT), which combines individual virtual reality (VR) assisted exposure therapy with group social and emotional rehabilitation skills training (will be superior to a treatment consisting of the same VR- exposure and group psychoeducational group therapy. Outcome will be assessed using relevant clinical, process, and cost outcomes. Additionally, we will assess the potential of olfactory stimulation as a trigger for PTSD symptoms of intrusive thoughts and re-experiencing. Therefore, this proposal will integrate clinical and neurobiological assessment studies designed to understand the role of these factors in the etiology, maintenance, and treatment of PTSD.
Specific Aims: There are three specific aims: First, we will evaluate the efficacy of Trauma Management Therapy (TMT) for the treatment of PTSD in OIF/OEF and determine if TMT (which combines exposure and social/emotional rehabilitation) improves social/emotional functioning compared to our comparison group (exposure plus psychoeducational group therapy). Second, we will explore olfactory activation patterns that may aid understanding of brain mechanisms in PTSD. Third, we will determine TMT's cost efficacy using treatment expenses and resource utilization measures.
Study Design: In a prospective randomized clinical trial we will test the superiority of TMT for OIF/OEF veterans with PTSD compared to exposure therapy plus psychoeducational group therapy. TMT combines VR assisted exposure therapy (VR-EXP) with social and emotional rehabilitation (SER). In addition to clinical, process, and cost outcomes relevant to PTSD for this population, we will include fMRI assessment of the central olfactory system in order to document its hypothesized role in fear acquisition and maintenance. Relevant outcome domains will be reassessed at mid-treatment, post-treatment, and 3- and 6-month follow-up.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32816
- University of Central Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Veterans or active duty military personnel with combat-related PTSD as a result of deployment to Iraq or Afghanistan.
Exclusion criteria:
- Personnel with acute cardiac difficulties (angina, myocardial infarction, and severe hypertension) will initially be excluded from the study due to concern that intensive EXP, often accompanied by temporary increases in heart rate and blood pressure, may pose risks of exacerbating cardiac status. They will be included once they are cleared by the cardiologist.
- Veterans with comorbid Axis I psychotic disorders or acute substance abuse disorders initially will be excluded from the study but will be eligible once their substance abuse is under control for at least two weeks. Additionally, an Axis II diagnosis of antisocial personality disorder will be reason for exclusion.
- Because PTSD typically is accompanied by high rates of comorbid psychiatric disorders (Keane & Wolfe, 1990), patients with comorbid depressive disorders, anxiety disorders, and personality disorders other than Antisocial Personality Disorder will be included. Also, veterans who have a diagnosis of mild Traumatic Brain Injury will be included, in order that our sample is as representative of OIF/OEF veterans as possible. We will address the issue of comorbid mTBI in the data analysis. In all cases included, PTSD must be considered the primary disorder.
- Patients must have a symptom duration of at least 6 months.
- Patients on benzodiazepines will be given an opportunity to discontinue and will be off benzodiazepines for at least two weeks prior to beginning the study. This exclusion is based on the empirical evidence to suggest that the efficacy of EXP for other anxiety disorders may be attenuated by benzodiazepines (Gray, 1987; Wardle, 1990). Patients on SSRI antidepressant medication for PTSD (Ballenger et al., 2000; Brady et al., 2000) will be included once their medication regimen has stabilized for at least 2 weeks. SSRI medication dosage must remain stable throughout the course of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 17 week Trauma Management Therapy (TMT)
TMTconsists of 29 treatment sessions administered over a period of 3 weeks.
Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups.
Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy.
Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression.
The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
|
TMT consists of 29 treatment sessions administered over a period of 17 weeks.
After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER).
Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people).
All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded.
SER sessions will be 90 minutes.
The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
Other Names:
|
Experimental: 3 week Trauma Management Therapy (TMT)
Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks.
Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon.
Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people).
All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded.
SER sessions will be 90 minutes.
The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
|
Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks.
Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon.
Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people).
All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded.
SER sessions will be 90 minutes.
The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
Other Names:
|
Active Comparator: 17 week Exposure Therapy Control Arm
The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks.
After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
|
15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks.
After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician-Administered PTSD Scale (CAPS; Blake et al., 1990; Weathers & Litz, 1994; Weathers et al., 1999)
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
PTSD Symptom Severity
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life Questionnaire (QLQ; Evans & Cope, 1989)
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
|
Clinician-Administered PTSD Scale (Selected items)
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
We will examine a subset of the CAPS separately, using frequency and intensity ratings on 4 items (interest in activities, social detachment, range of affect, anger control).
These items were independently rated by 3 of the study investigators as being representative of social/emotional functioning
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Objective Functional Indicators
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
Data will be collected via a clinician-administered rating form regarding objective indicators of social functioning, such as changes in marital status, employment status, residential status, legal involvement, psychiatric hospitalization, and utilization of medical care.
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Clinical Global Impressions Scale
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
The Severity and Global Improvement Subscales are each 7-point scales which are part of the ECDEU Assessment Manual for Psychopharmacology.
They will be used to assess overall severity and improvement.
The CGI severity rating is a frequently used measure in pharmacological treatment studies and could be useful in making comparisons of rates of improvement from this study and those of drug studies.
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Health-Related Functioning: Medical Outcome Study Short Form-36 Health Survey
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
The SF-36 is a 36-item questionnaire that measures health status and functioning over the past four weeks
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Patient Ratings
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
For a one-week period at each assessment point, patients will keep a log of daily symptoms, such as nightmares, flashbacks, total hours of sleep, and exaggerated startle responses behavioral ratings to monitor the frequency and severity (on a 10-point scale) of PTSD
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
The PTSD Checklist (PCL-M; Weathers et al., 1993)
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
PTSD Symptom Severity
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Credibility
Time Frame: after week 3 for 17 week arms; after third day for 3 week arm
|
To assess for differences in outcome expectancy, treatment credibility scales developed by Borkovec and Nau (1972) will be used.
Four of the questions will be used for this study, with 10-point Likert scales.
These include questions regarding how logical the treatment seems, how confident participants are about treatment, and their expectancy of success.
|
after week 3 for 17 week arms; after third day for 3 week arm
|
Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS-VA; Frueh et al., 2002):
Time Frame: after 17 weeks for two study arms; after three weeks for the third study arm
|
The CPOSS-VA is 16-item measure, with a Likert scale response format, based on a general measure of patient satisfaction (Pellegrin et al., 2001).
|
after 17 weeks for two study arms; after three weeks for the third study arm
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deborah C Beidel, Ph.D., ABPP, University of Central Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCFlorida
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Combat Disorders
-
US Department of Veterans AffairsCompletedCombat Stress DisorderUnited States
-
Institut de Recherche Biomedicale des ArmeesRecruitingStress Disorder, CombatFrance
-
National University Hospital, SingaporeCompleted
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
University of ArizonaEunice Kennedy Shriver National Institute of Child Health and Human Development...Enrolling by invitationStress Disorders, Post-Traumatic | Combat Stress Disorders | Animal-Human BondingUnited States
-
VA Loma Linda Health Care SystemMultidisciplinary Association for Psychedelic StudiesRecruitingPost Traumatic Stress Disorder | Combat Stress DisordersUnited States
-
Claude Bernard UniversityCompleted
-
Synchroneuron Inc.WithdrawnPosttraumatic Stress Disorders | Stress Disorders, Post-Traumatic | Post-Traumatic Stress Disorders | Post-Traumatic Stress Disorders, Combat-related
-
Tel Aviv UniversityEnrolling by invitationMilitary Combat PerformanceIsrael
-
Southern California Institute for Research and...VA Office of Research and DevelopmentUnknown
Clinical Trials on Trauma Management Therapy
-
VA Office of Research and DevelopmentCompleted
-
University of BaselUniversity of ZurichRecruitingMotivation | Alliance, TherapeuticSwitzerland
-
McMaster UniversityWorkplace Safety and Insurance BoardNot yet recruitingPost-Traumatic Stress Disorder
-
The Center for Victims of Torture, United StatesUniversity of Minnesota; HealthEast Care SystemUnknownDelivery of Intensive Behavioral Services to Refugees in Primary Care
-
NYU Langone HealthSubstance Abuse and Mental Health Services Administration (SAMHSA)Recruiting
-
VA Office of Research and DevelopmentCompletedStress Disorders, Post-traumaticUnited States
-
University of Hamburg-EppendorfRecruitingPsychotic Disorders | PTSD | Schizophrenia | Post Traumatic Stress Disorder | PsychosisGermany
-
Trauma Institute & Child Trauma InstituteGratis FoundationUnknownTrauma, Psychological | Conflict, InterparentalUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedAlcoholism | Sexually Transmitted Diseases, Viral | Sexual Behavior | Sexual Abuse | Child Abuse, SexualUnited States
-
Universität Duisburg-EssenCompleted